<DOC>
	<DOCNO>NCT00447681</DOCNO>
	<brief_summary>This randomize , double-blind placebo-controlled inpatient/outpatient , sequential group study ascend single IV dose ILV-094 , investigational drug , administer healthy subject . In addition , one sub-cutaneous dose cohort , follow 25 mg IV dose .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics Pharmcodynamics ILV-094 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy subject ( Men woman nonchildbearing potential ) , age 18 50 year . Body mass index range 18 30 Kg/m2 body weight great 50 Kg . Healthy determine investigator basis medical history , physical examination , clinical laboratory test result , vital sign , 12lead electrocardiogram .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>